摘要
目的探讨慢性乙肝(CHB)肝硬化失代偿期患者给予复方鳖甲软肝片联合富马酸丙酚替诺福韦片治疗疗效。方法选取2020年8月至2021年7月灵宝市城南医院收治的78例CHB肝硬化失代偿期患者,按照随机摸球法分成治疗组(39例)与对照组(39例),对照组给予富马酸丙酚替诺福韦片治疗,治疗组采用复方鳖甲软肝片联合富马酸丙酚替诺福韦片,比较两组临床疗效、肝功能指标、肝纤维化指标及肝硬度数值。结果治疗组治疗有效率(94.87%)高于对照组(76.92%),差异有统计学意义(P<0.05)。两组治疗后白蛋白(ALB)水平明显提高,差异有统计学意义(P<0.05),丙氨酸氨基转移酶(ALT)、总胆红素(TBIL)水平明显降低,差异有统计学意义(P<0.05),且治疗组与对照组相比ALB水平明显更高,差异有统计学意义(P<0.05),ALT、TBIL水平明显更低,差异有统计学意义(P<0.05)。两组治疗后透明质酸(HA)、层粘连蛋白(LN)、Ⅲ型前胶原(PCⅢ)水平明显降低,差异有统计学意义(P<0.05),且治疗组与对照组相比明显更低,差异有统计学意义(P<0.05)。两组治疗后肝硬度数值明显降低,差异有统计学意义(P<0.05),且治疗组与对照组相比明显更低,差异有统计学意义(P<0.05)。结论CHB肝硬化失代偿期患者给予复方鳖甲软肝片联合富马酸丙酚替诺福韦片治疗,能够提高临床疗效,改善患者肝功能及肝纤维化指标,降低肝硬度数值。
Objective To investigate the therapeutic effect of compound Biejia Ruangan tablets combined with propofol tenofovir fumarate tablets on patients with chronic hepatitis B(CHB)cirrhosis in the decompensation stage.Methods From August 2020 to July 2021,78 patients with CHB cirrhosis in decompensated stage in Chengnan Hospital of Lingbao city were selected and divided into treatment group(39 cases)and control group(39 cases)according to the method of random ball touch.The control group was treated with propofol tenofovir fumarate tablets.The treatment group was treated with compound Biejia Ruangan tablets combined with propofol tenofovir fumarate tablets.The clinical efficacy,liver function indicators,liver fibrosis indicators and liver hardness values of the two groups were compared.Results The effective rate of the treatment group(94.87%)was higher than that of the control group(76.92%),the difference was statistically significant(P<0.05).After treatment,the level of albumin(ALB)was significantly increased in the two groups,and the difference was statistically significant(P<0.05).The levels of alanine aminotransferase(ALT)and total bilirubin(TBIL)was significantly decreased in the two groups,and the difference was statistically significant(P<0.05),and the levels of ALB in the treatment group were significantly higher than those in the control group,the difference was statistically significant(P<0.05),the levels of ALT and TBIL in the treatment group were lower than those in the control group,the difference was statistically significant(P<0.05).After treatment,the levels of hyaluronic acid(HA),laminin(LN)and procollagen typeⅢ(PCⅢ)in the two groups were significantly lower,the difference was statistically significant(P<0.05),the treatment group were lower than the control group,the difference was statistically significant(P<0.05).After treatment,the liver hardness value of the two groups was significantly lower(P<0.05),the treatment group were lower than the control group,the difference was statistically significant(P<0.05).Conclusion The treatment of patients with CHB cirrhosis in decompensated period with compound Biejia Ruangan tablets combined with propofol tenofovir fumarate tablets can improve the clinical efficacy,improve the liver function and liver fibrosis index of patients,and reduce the liver hardness value.
作者
王万丰
WANG Wanfeng(Department of Internal Medicine,Chengnan Hospital of Lingbao City,Sanmenxia Henan 472500,China)
出处
《临床研究》
2023年第3期107-110,共4页
Clinical Research
关键词
慢性乙肝肝硬化失代偿期
复方鳖甲软肝片
富马酸丙酚替诺福韦片
肝功能
decompensation period of chronic hepatitis B cirrhosis
compound Biejia Ruangan tablets
propofol tenofovir fumarate tablets
liver function